Meta AnalysisID 5669
口服中成药联合化疗治疗胃癌的有效性与安全性：贝叶斯网状Meta分析
CRD42020168840
How does oral Chinese patent medicine combined with chemotherapy impact on efficacy and safety of gastric cancer compared to chemotherapy alone?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5669
- Evidence Id
- 14227
- Core Evidence Id
- 14227
- Source Meta Analysis Id
- 5649
- Herb2 Meta Analysis Id
- HBMA005649
- Crd Id
- CRD42020168840
- Title
- Effectiveness and safety of oral Chinese patent medicines combined with chemotherapy for gastric cancer : A Bayesian network meta-analysis
- Review Question
- How does oral Chinese patent medicine combined with chemotherapy impact on efficacy and safety of gastric cancer compared to chemotherapy alone?
- Study Type Included
- Rndomized controlled trials (RCTs)
- Condition Being Studied
- gastric cancer. oral Chinese patent medicine.
- Participant
- Patients with definite pathological diagnosis of gastric cancer have unlimited stages, age ≥ 18 years old, no limitation of gender, race, nationality, etc. There is at least one measurable clinical or imaging observation index, with Karnofsky (KPS) score ≥ 60 or Eastern Cooperative Oncology Group (ECOG) score of 0-2. There is no chemotherapy contraindication before treatment, and there is no obvious abnormality in liver and kidney function, hematology, electrocardiograph (ECG).
- Animal
- Human Disease Modelled
- Intervention
- Under the guidance of the theory of traditional Chinese medicine, in order to prevent and treat diseases, traditional Chinese medicine is processed into a certain dosage form of traditional Chinese medicine products according to the prescribed prescription and preparation process, which is approved by the State Drug Administration. As a traditional Chinese medicine for clinical application, not only the relative drug name, dosage, specification and specific quality standards are required The test method should have improved efficacy, clear scope of application, application taboos and precautions. These oral Chinese patent medicines are recommended by the Clinical Practice Guidelines of Chinese Medicine in Oncology and included in the National Basic Medical Insurance Drugs List of China, specifically Bailing capsule (BL), Jianpi Yishen granule (JPYS), Zhenqi Fuzheng capsule / granule / tablet (ZQFZ), Bazhen granule / capsule / pill / tablet (BZ), Buzhong Yiqi pill (BZYQ), Shiquan Dabu pill (SQDB), Xiao’aiping tablet / capsule / drop pill (XAP), Cinobufacin tablet / capsule (HCS), Antike capsule (ATK) , Pingxiao capsule / tablet (PX), Andolin capsule (ADL), Yangyin Shengxue mixture (YYSX), Shiyiwei Shengqi tablet / capsule (SYWSQ), Shenqi Shiyiwei granule (SQSYW) and Kanglaite soft capsule (KLT) .
- Comparator Control
- The control groups include chemotherapy alone or another oral Chinese patent medicine combined with chemotherapy.
- Main Outcome
- Objective response rate (ORR); Performance status Measures of effect ORR will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) . ORR = [Complete Response (CR) + Partial Response (PR) ] / total cases × 100%. Performance status will be assessed by KPS score. After treatment, KPS scores increased by more than 10 points were considered effective.
- Outcome Measure
- Additional Outcome
- Adverse drug reactions (ADRs) involving the incidence of leucopenia and gastrointestinal reaction. Measures of effect The incidence of ADRs = number of ADRs / total cases × 100%.
- Study Method
- 网络荟萃分析, 前瞻性荟萃分析（PMA）, 系统评价
- Keyword
- Humans
- Contact
- Xiaona Lu [email protected]
- Organisational Affiliation
- Nanjing University of Chinese Medicine http://www.njucm.edu.cn/
- Funding Source
- National Natural Science Foundation of China (Project Number: 81673918) .
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-02-12
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2020-01-30
- Anticipated Completion Date
- 2020-06-30
- Title Cn
- 口服中成药联合化疗治疗胃癌的有效性与安全性：贝叶斯网状Meta分析
- Title En
- Effectiveness and safety of oral Chinese patent medicines combined with chemotherapy for gastric cancer : A Bayesian network meta-analysis
- Bilingual Status
- complete